A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy

2017 ◽  
Vol 49 (8) ◽  
pp. 738-742 ◽  
Author(s):  
Monique J. Vanaman Wilson ◽  
Isabela T Jones ◽  
Douglas C. Wu ◽  
Mitchel P. Goldman
2017 ◽  
Vol 49 (9) ◽  
pp. 810-818 ◽  
Author(s):  
Christiane Bay ◽  
Anne-Cathrine Vissing ◽  
Daniel Thaysen-Petersen ◽  
Catharina Margrethe Lerche ◽  
Katrine Togsverd-Bo ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Gita Faghihi ◽  
Saghi Fatemi-Tabaei ◽  
Bahareh Abtahi-Naeini ◽  
Amir Hossein Siadat ◽  
Giti Sadeghian ◽  
...  

Background. Tretinoin has been shown to improve photoaged skin. This study was designed to evaluate the efficacy and tolerability of a 5% retinoic acid peel combined with microdermabrasion for facial photoaging. Materials and Methods. Forty-five patients, aged 35–70, affected by moderate-to-severe photodamage were enrolled in this trial. All patients received 3 sessions of full facial microdermabrasion and 3 sessions of either 5% retinoic acid peel or placebo after the microdermabrasion. Efficacy was measured using the Glogau scale. Patients were assessed at 2 weeks and 1, 2, and 6 months after treatment initiation. Results. The mean ± SD age of participants was 49.55±11.61 years, and the majorities (73.3%) were female. Between 1 month and 2 months, participants reported slight but statistically significant improvements for all parameters (P<0.001). In terms of adverse effects, there were statistically significant differences reported between the 5% retinoic acid peel groups and the control group (P<0.001). The majority of adverse effects reported in the study were described as mild and transient. Conclusion. This study demonstrated that 5% retinoic acid peel cream combined with microdermabrasion was safe and effective in the treatment of photoaging in the Iranian population. This trial is registered with IRCT2015121112782N8.


Therapy ◽  
2005 ◽  
Vol 2 (6) ◽  
pp. 883-888 ◽  
Author(s):  
Bagher Larijani ◽  
Mohammad Pajouhi ◽  
Mohammad Hasan Bastanhagh ◽  
Alireza Sadjadi ◽  
Shahriar Aghakhani ◽  
...  

1998 ◽  
Vol 26 (1) ◽  
pp. 56-60 ◽  
Author(s):  
F. J. Munro ◽  
S. J. Young ◽  
I. J. Broome ◽  
H. M. Robb ◽  
G. J. Wardall

In a double-blind, placebo-controlled clinical trial (power of 80% to detect a 30% reduction in morphine consumption, P<0.05) we have determined that intraoperative intravenous administration of tenoxicam 40 mg during laparoscopic cholecystectomy, when compared with placebo, was associated with a significant reduction in consumption of morphine at 6 hours and 12 hours (P<0.05) but not at 24 hours, when assessed by patient-controlled analgesia. Furthermore there was a significantly greater requirement for “rescue” analgesia with intramuscular morphine in the placebo group during the period of the study. There was no difference between the groups in pain scores, either at rest or on movement, nor in the incidence of nausea and vomiting. No patient in either group suffered a respiratory rate less than 8/min or oversedation at any time, and there were no other adverse effects.


1998 ◽  
Vol 87 (2) ◽  
pp. 86-88
Author(s):  
D P Rastogi ◽  
V P Singh ◽  
Vikram Singh ◽  
S K Dey ◽  
K Rao

Sign in / Sign up

Export Citation Format

Share Document